DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells

European Journal of Immunology

Volumn 37, Issue 9, 2007, Pages 2378-2389

  Baron, Udo ^a   Floess, Stefan ^b   Wieczorek, Georg ^a   Baumann, Katrin ^b   Grützkau, Andreas ^c   Dong, Jun ^c   Thiel, Andreas ^c   Boeld, Tina J ^d   Hoffmann, Petra ^d   Edinger, Matthias ^d   Türbachova, Ivana ^a   Hamann, Alf ^b   Olek, Sven ^a   Huehn, Jochen ^b  

^a EPIONTIS GMBH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

DNA methylation; Epigenetic modifications; Treg marker

Indexed keywords

DNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELL SPECIFICITY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENOME IMPRINTING; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; WIDE HYBRIDIZATION;

CALCIUM-BINDING PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DNA METHYLATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548755672     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737594     Document Type: Article

References (49)

1. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005. 6: 345-352.
2. Baecher-Allan, C. and Hafler, D. A., Suppressor T cells in human diseases. J. Exp. Med. 2004. 200: 273-276.
3. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004. 199: 971-979.
4. + regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 2004. 199: 1285-1291.
5. Huan, J., Culbertson, N., Spencer, L., Bartholomew, R., Burrows, G. G., Chou, Y. K., Bourdette, D. et al., Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 2005. 81: 45-52.
6. Offner, H. and Vandenbark, A. A., Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS. Int. Rev. Immunol. 2005. 24: 447-477
7. + regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 2006. 83: 1432-1446.
8. Takahashi, M., Nakamura, K., Honda, K., Kitamura, Y., Mizutani, T., Araki, Y., Kabemura, T. et al., An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig. Dis. Sci. 2006. 51: 677-686.
9. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 2005. 92: 913-920.
10. Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F. and Korangy, F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005. 65: 2457-2464.
11. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 2006. 24: 1169-1177.
12. Zou, W., Regulatory T cells, turnout immunity and immunotherapy. Nat. Rev. Immunol. 2006. 6: 295-307.
13. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X, Cheng, P., Mottram, P., Evdemon-Hogan, M. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
14. Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet A. G., Muller-Holzner, E., Deibl, M. et al., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 2005. 11: 8326-8331.
15. + regulatory Tcells in patients with multiple myeloma. Blood 2006. 107: 3940-3949.
16. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006. 1: E129.
17. Curiel, T. J., Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 2007. 117: 1167-1174.
18. Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L. and Banham, A. H., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 2006. 24: 5373-5380.
19. Zheng, Y. and Rudensky, A. Y., Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 2007. 8: 457-462.
20. Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G. and Rudensky, A. Y., Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005. 22: 329-341.
21. Wan, Y. Y. and Flavell, R. A., Identifying Foxp3-expressing suppressor Tcells with a bicistronic reporter. Proc. Natl. Acad. Sci. USA 2005. 102: 5126-5131.
22. + regulatory T cells induces a scurfy-like disease. J. Exp. Med. 2007. 204: 57-63.
23. -T cells. J. Clin. Invest. 2003. 112: 1437-1443.
24. + regulatory T cells. Int. Immunol. 2004. 16: 1643-1656.
25. + regulatory T cells at the single-cell level. Eur. J. Immunol. 2005. 35: 1681-1691.
26. Ziegler, S. F., FOXP3: Not just for regulatory T cells anymore. Eur. J. Immunol. 2007. 37: 21-23.
27. + T regulatory cells in humans. Hum. Immunol. 2005. 66: 13-20.
28. Mantel, P. Y., Ouaked, N., Ruckert, B., Karagiannidis, C., Welz, R., Blaser, K. and Schmidt-Weber, C. B., Molecular mechanisms underlying FOXP3 induction in human T cells. J. Immunol. 2006. 176: 3593-3602.
29. Gavin, M. A., Torgerson, T. R., Houston, E., Deroos, P., Ho, W. Y., Stray-Pedersen, A., Ocheltree, E. L. et al., Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 2006. 103: 6659-6664.
30. + T cells. Eur. J. Immunol. 2007. 37: 129-138.
31. Pillai, V., Ortega, S. B., Wang, C. K. and Karandikar, N. J., Transient regulatory T-cells: A state attained by all activated human T-cells. Clin. Immunol. 2007. 123: 18-29.
32. Allan, S.E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bacchetta, R., Roncarolo, M. G. and Levings, M. K., Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007. 19: 345-354.
33. Floess, S., Freyer, J., Siewert, C., Baron, U., Olek, S., Polansky, J., Schlawe, K. et al., Epigenetic control of the foxp3 locus in regulatory Tcell. PLOS Biol. 2007 5: E38.
34. Reik, W., Dean, W. and Walter, J., Epigenetic reprogramming, in mammalian development. Science 2001. 293: 1089-1093.
35. Bird, A., DNA methylation patterns and epigenetic memory. Genes Dev. 2002. 16: 6-21.
36. Baron, U., Türbachova, L, Hellwag, A., Eckhardt, F., Berlin, K, Hoffmuller, U., Gardina, P. and Olek, S., DNA methylation analysis as a tool for cell typing. Epigenetics 2006. 1: 55-60.
37. Eckhardt, F., Lewin, J., Cortese, R., Rakyan, V. K., Attwood, J., Burger, M., Burton, J. et al., DNA methylation profiling of human chromosomes, 6, 20 and 22. Nat. Genet. 2006. 38: 1378-1385.
38. Carrel, L. and Willard, H. F., X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005. 434: 400-404.
39. Huang, T. H., Perry, M. R. and Laux, D. E., Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 1999. 8: 459-470.
40. Wahl, S. M. and Chen, W., Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res. Ther. 2005. 7: 62-68.
41. high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006. 108: 4260-4267.
42. Zuo, T., Wang, L., Morrison, C., Chang, X, Zhang, H., Li, W., Liu, Y. et al., FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007. 129: 1275-1286.
43. Bouche, N., Scharlat, A., Snedden, W., Bouchez, D. and Fromm, H., A novel family of calmodulin-binding transcription activators in multicellular organisms. J. Biol. Chem. 2002. 277: 21851-21861.
44. Katoh, M. and Katoh, M., Identification and characterization of FLJ10737 and CAMTA1 genes on the commonly deleted region of neuroblastoma at human chromosome lp36.31-p36.23. Int. J. Oncol. 2003. 23: 1219-1224.
45. Nakatani K., Nishioka, J., Itakura, T., Nakanishi, Y., Horinoucbi, J., Abe, Y. Wada, H. and Nobori, T., Cell cycle-dependent transcriptional, regulation of calmodulin-binding transcription activator 1 in neuroblastoma cells. Int. J. Oncol. 2004. 24: 1407-1412.
46. Henrich, K. O., Fischer, M., Mertens, D., Benner, A., Wiedemeyer, R., Brors, B., Oberthuer, A. et al., Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin. Cancer Res. 2006. 12: 131-138.
47. + regulatory Tcells. J. Exp. Med. 2004. 199: 303-313.
48. Olek, A., Oswald, J. and Walter, J., A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996. 24: 5064-5066.
49. Lewin, J., Schmitt, A. O., Adorjan, P., Hildmann, T. and Piepenbrock, C., Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004. 20: 3005-3012.